Double blind, Randomize control trial ; Intraarticular triamcinolone acetone post arthroscopic lysis adhesion prevent recurrent stiffness of the knee.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200322005

Enrollment

Registered

2020-03-22

Start date

2020-01-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Study on knee range of motion and pain score after arthroscopic release of stiff knee Stiff knee Arthroscopic release TA injection

Interventions

TA intraarticular injection after arthroscopic release of stiff knee,NSS intraarticular injection after arthroscopic release of stiff knee

Active Comparator Procedure/Surgery,Placebo Comparator No treatment

TA injection,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: -Patient who was diagnosed as Arthrofibrosis knee and under went arthroscopic lysis adhesion.

Exclusion criteria

Exclusion criteria: Active infection Extra-articular course stiff knee Chronic inflammatory joint disease (RA SLE) Knee stiffness from tumor Nerve or spine injury Previous operative management of stiff knee.

Design outcomes

Primary

Measure	Time frame
Knee ROM at 1, 6, 12 week post operative at 1, 6, 12 week post operative Range of motion as degree	—

Secondary

Measure	Time frame
VAS at 1, 6, 12 week post operative at 1, 6, 12 week post operative Visual analog score	—

Countries

Thailand

Contacts

Public ContactWachiraparn Parinyakhup

Faculty of Medicine, Princ of Songkla University

Chai069-084@hotmail.com0866911384

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Double blind&#44; Randomize control trial ; Intraarticular triamcinolone acetone post arthroscopic lysis adhesion prevent recurrent stiffness of the knee.